Why the study?
This study explored 1-year follow-up of a pharmaco-invasive strategy with half-dose recombinant human prourokinase in patients with acute STEMI.
Does a pharmaco-invasive strategy with half-dose recombinant human prourokinase reduce MACEs compared to primary PCI in patients with STEMI?
Does a pharmaco-invasive strategy with half-dose recombinant human prourokinase reduce MACEs compared to primary PCI in patients with STEMI?
Answers are grounded in this paper and cite their sources.
A pharmaco-invasive strategy with half-dose prourokinase shortens FMC-reperfusion time and reduces procedural complications without increasing bleeding or 1-year MACEs compared to primary PCI in STEMI patients.
This study explored 1-year follow-up of Parmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP) in patients with acute ST-segment elevation myocardial infarction (STEMI). The follow-up endpoints were major adverse cardiovascular events (MACEs) occurring within 30 days and 1 year, as well as postoperative bleeding events. The study ultimately included 150 subjects, with 75 in the primary percutaneous coronary intervention (PPCI) group and 75 in the PHDP group. This study found that the PHDP group had a shorter FMC-reperfusion time (42.00 min vs 96.00 min, P < 0.001). During PCI, the PHDP group had a lower percutaneous transluminal coronary angioplasty (PTCA) (P = 0.021), intropin (P = 0.002) and tirofiban (P < 0.001) use. And the incidence of intraoperative arrhythmia, malignant arrhythmia, and slow flow/no-reflow was lower in the PHDP group (P < 0.001). At the 30-day follow-up, there was a significantly higher proportion of patients in the PPCI group who were readmitted due to unstable angina (P = 0.037). After 1 year of follow-up, there was no statistically significant difference in MACEs between the two groups (P = 0.500). The incidence of postoperative major bleeding, intracranial bleeding, and minor bleeding did not differ between the PHDP and PPCI groups (P > 0.05). The PHDP facilitates early treatment of infarct-related vessels, shortens FMC-reperfusion time, and does not increase the risk of MACEs.
No takes yet. Share an insight, caveat, or question.
Dou et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: